Pine Pharmaceuticals Opens Manufacturing Complex in Tonawanda, New York
05/04/2018
Alfonse Muto, Owner, Pine Pharmaceuticals LLC said," Pine Pharmaceuticals has been committed to delivering the highest quality compounded products for over 30 years. Thanks to the support of New York State and the Erie County IDA we have been able to expand, create new jobs and continue preparing the highest quality products."
The 25,000-square-foot manufacturing facility for Pine Pharmaceuticals includes several clean rooms and provides the company with nearly six times the space that it previously had in its leased facility. It was designed from the ground up to comply with the US Food and Drug Administration's Current Good Manufacturing Practice.
Pine Pharmaceuticals provides pharmaceutical compounding, including specialized sterile formulations serving ophthalmologists, retinal specialists, hospitals, medical practices and clinics.
The sterile compounded preparations are made to order and formulated using cutting-edge technology and industry-leading quality assurance practices. Also, as an FDA-registered 503B Outsourcing Facility, Pine Pharmaceuticals has the unique ability to address drug shortages by working with hospitals, clinics, medical practices and physician offices to provide sterile compounded pharmaceuticals.
Pine Pharmaceuticals is receiving $500,000 in refundable tax credits from the state's Excelsior Jobs Program and a 136-kilowatt low-cost power allocation from the New York Power Authority's ReCharge NY program if it meets its job-creation and investment targets. The company currently has 15 employees and has pledged to create 12 new high-paying jobs within two years. By 2021, the company has promised to create 28 new positions. The company also received $1.2 million in tax breaks from the Erie County Industrial Development Agency to build the manufacturing facility.
"I am proud of the State's support for companies like Pine Pharmaceuticals. Their expansion shows that they're confident investing money in Western New York while creating new jobs and helping to grow our high-tech manufacturing industry," said Lieutenant Governor Kathy Hochul. "Projects like this that utilize the talents of our highly skilled and dedicated workforce are what will continue to build our communities and strengthen our economy for generations to come."
"New York continues to make major investments in manufacturing, bioscience, and workforce development," Governor Andrew Cuomo said. "With this grand opening for Pine Pharmaceuticals, we are further establishing Western New York's reputation as a thriving hub of high-tech manufacturing and are continuing this region's momentum."
Empire State Development President, CEO and Commissioner Howard Zemsky said, "Pine Pharmaceuticals expansion in New York State is another example of how we are successful creating new jobs and growing capital investment within the region.
" Gil C. Quiniones, NYPA President & CEO, said, "Pine Pharmaceuticals opening in Tonawanda is great news for Western New York. The Governor's ReCharge NY program has been a significant catalyst for job creation and retention throughout the state and this is an excellent example of its impact."
Project Announcements
Wyandot Snacks Expands Marion, Ohio, Production Operations
08/29/2025
Trane Technologies Expands Fort Smith, Arkansas, Operations
08/29/2025
BioMADE Plans Boone, Iowa, Bioindustrial Manufacturing Operations
08/29/2025
Choice Fabricators Expands Rainbow City, Alabama, Production Operations
08/29/2025
Ranovus Expands Ottawa, Ontario, Semiconductor Operations
08/29/2025
Belgium-Based Stow Group Plans Gordon County, Georgia, Manufacturing Operations
08/28/2025
Most Read
-
Tariffs, Talent, and U.S. Expansion
Q3 2025
-
What We’re Getting Wrong About Gen Z’s Future in the Skilled Trades
Q3 2025
-
Data Center Demand Stabilizes Amid Changing Market Forces
Q3 2025
-
A New Course for U.S. Shipbuilding
Q3 2025
-
Optimizing Your Rail-Served Transportation Network: Strategy Before Steel
Q2 2025
-
In Focus: AI Is Changing Incentives Math
Q2 2025
-
Rewriting the Rules of Warehouse ROI
Q3 2025